Tests CPAP treatment in adults with sleep apnea and optic nerve damage
Tests CPAP breathing device use in adults with sleep apnea and optic nerve damage.
Plain-language title generated from the registry record
Registry title: Optic Nerve Injury in Obstructive Sleep Apnea Patients
Key facts
- Where
- Nanjing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with newly diagnosed obstructive sleep apnea. They will use CPAP for 3 months, and their sleep and eyes will be checked before and after.
- Age
- 18 to 80 years
- Sex
- All sexes can join.
- Disease stage
- Obstructive sleep apnea (apnea-hypopnea index of 5 per hour or more), first-time diagnosis. People are grouped as mild, moderate or severe.
- Earlier treatment
- No earlier surgery or CPAP treatment for sleep apnea.
- Biomarker or test result
- Apnea-hypopnea index of 5 per hour or more.
Main reasons for not taking part
- History of severe stroke or brain bleeding, or nerve or mental health conditions that could affect results
- Active cancer or other severe disease, such as severe liver or kidney problems
- Diabetes or other significant blood vessel diseases
- Severe COPD, severe asthma, severe pulmonary hypertension or heart failure
- Pregnancy, or being extremely weak or having other severe underlying conditions
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06748703, who can take part
Where in China
- The First Affiliated Hospital of Nanjing Medical UniversityNanjing, ChinaContact: Ning Ding, doctorTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Nanjing Medical University
- Trial code
- NCT06748703
- Record updated
- 27 June 2025
- Original description
Ischemic optic neuropathy (ION) is damage to the optic nerve caused by ischemia and hypoxia of the optic nerve due to an impairment of the blood supply to the optic nerve from the arteries. Obstructive Sleep Apnea Hypoventilation Syndrome (OSAHS) is a sleep-breathing disorder characterized by recurrent upper airway obstruction and apnea during sleep, leading to recurrent intermittent hypoxemia with fragmented sleep and daytime sleepiness. Due to the lack of accurate methods to evaluate blood flow, the correlation between the two is unclear and uncertain. The study will enroll 80 patients from the First Affiliated Hospital of Nanjing Medical University and categorize them into mild, moderate, and severe OSA groups according to their apnea-hypopnea index (AHI). Participants will undergo a baseline evaluation, including polysomnography (PSG) and ophthalmologic examinations such as optic nerve and macular blood flow OCT, visual acuity, refraction, intraocular pressure, and visual fields. Eligible patients will be treated with CPAP for 3 months, after which their PSG and ophthalmologic examination-related results will be re-evaluated to assess treatment efficacy.Read full original descriptionShow less
Optic Nerve Injury and the Effect of CPAP Treatment in Obstructive Sleep Apnea Patients
Ischemic optic neuropathy (ION) is damage to the optic nerve caused by ischemia and hypoxia of the optic nerve due to an impairment of the blood supply to the optic nerve from the arteries. Obstructive Sleep Apnea Hypoventilation Syndrome (OSAHS) is a sleep-breathing disorder characterized by recurrent upper airway obstruction and apnea during sleep, leading to recurrent intermittent hypoxemia with fragmented sleep and daytime sleepiness. Due to the lack of accurate methods to evaluate blood flow, the correlation between the two is unclear and uncertain. The study will enroll 80 patients from the First Affiliated Hospital of Nanjing Medical University and categorize them into mild, moderate, and severe OSA groups according to their apnea-hypopnea index (AHI). Participants will undergo a baseline evaluation, including polysomnography (PSG) and ophthalmologic examinations such as optic nerve and macular blood flow OCT, visual acuity, refraction, intraocular pressure, and visual fields. Eligible patients will be treated with CPAP for 3 months, after which their PSG and ophthalmologic examination-related results will be re-evaluated to assess treatment efficacy.
Inclusion: Patients aged between 18 and 80 years; Diagnosed with Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS)(apnea-hypopnea index≥5/h); First-time diagnosis, with no previous surgical interventions or CPAP treatment for OSA; Ability and willingness to provide informed consent for participation in the study.
Exclusion: History of severe stroke or cerebral hemorrhage, or presence of neurological or psychiatric conditions that could affect study results; Presence of active malignancies or other severe underlying diseases, such as severe liver or kidney dysfunction. Diagnosed with diabetes or other significant vascular diseases; Presence of severe chronic obstructive pulmonary disease (COPD), severe asthma, severe pulmonary hypertension, or heart failure caused by any condition; Pregnancy or having other conditions that make participation in this study unsuitable; Extremely debilitated patients or those with severe underlying conditions.